Skip to main content
Figure 5 | Molecular Neurodegeneration

Figure 5

From: rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration

Figure 5

Soluble and insoluble α-synuclein levels increase over time upon delivery of rAAV2/7-α-synuclein WT or A53T. (A) Western blot and (B) quantitative analysis (n = 3) of soluble α-synuclein in the cytoplasmic (TBS soluble) fraction of SN mouse lysates injected with rAAV2/7-eGFP (4 weeks time point) or rAAV2/7-α-synuclein WT or A53T (5 days, 2 weeks and 4 weeks time points). (C) Immunoblotting and (D) quantification (n = 3) of phosphorylated and detergent-insoluble α-synuclein in the Urea soluble fraction of injected mouse nigral homogenates. For detection, immunoblots for α-synuclein were performed using a panel of different antibodies against: mouse and human α-synuclein (Syn1), specific human α-synuclein (15G7) and P-S129 α-synuclein. GAPDH and β-actin serve as internal loading control in the TBS and Urea fractions, respectively.

Back to article page